Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14186018 | 1.00 | OPRM1 (1.00) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL4913077 | 1.00 | OPRM1 (1.00) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL6585522 | 1.00 | OPRM1 (1.00) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL4921324 | 1.00 | OPRM1 (1.00) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL6591096 | 0.99 | OPRM1 (0.97) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL5771940 | 0.94 | OPRM1 (0.88) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL4920194 | 0.93 | OPRM1 (0.86) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL12204966 | 0.89 | OPRM1 (0.80) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL4909235 | 0.89 | OPRM1 (0.79) | OPRM1OPRL1OPRK1CHRM1CHRM2 | |
| SCHEMBL14515243 | 0.88 | OPRM1 (0.78) | OPRM1OPRL1OPRK1CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103163-A1 | Antipruritics | OYAMA TATSUYA | 2008-05-01 | — | — | US | disclosed |
| US-20080103162-A1 | Antipruritics | OYAMA TATSUYA | 2008-05-01 | — | — | US | disclosed |
| EP-0990653-B1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20040116450-A1 | Antipruritics | NIPPON SHINYAKU CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1371376-A1 | ANTIPRURITICS | Nippon Shinyaku Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
| US-6258825-B1 | ANALGESIC, A RELIEVER AGAINST TOLERANCE TO A NARCOTIC ANALGESIC REPRESENTED BY MORPHINE, REMEDY FOR PARKINSONISM, A REMEDY FOR CHOREA, AN ANTIDEPRESSANT, A REMEDY FOR DIABETES INSIPIDUS, A REMEDY FOR POLYURIA, OR HYPOTENSION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103162-A1 | Antipruritics | ITCH, NTSR1, OPRL1 | OPRM1 158/4885OPRL1 3/4885OPRK1 37/4885 |
| US-20080103163-A1 | Antipruritics | ITCH, OPRL1, NTSR1 | OPRM1 135/4885OPRL1 2/4885OPRK1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.